Interferon-α/β receptor as a prognostic marker in osteosarcoma

Journal of Bone and Joint Surgery

Volumn 93, Issue 6, 2011, Pages 519-526

  Kubo, Tadahiko ^a   Shimose, Shoji ^a   Matsuo, Toshihiro ^a   Fujimori, Jun ^a   Arihiro, Koji ^b   Ochi, Mitsuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; CISPLATIN; DOXORUBICIN; METHOTREXATE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 79952756697     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.J.00198     Document Type: Article

References (34)

1. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452-8. (Pubitemid 28309040)
2. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, Donati D, Lari S, Forni C, DePaolis M. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001;37:2030-9. (Pubitemid 32938106)
3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:776-90. (Pubitemid 34111386)
4. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-28.
5. Eselgrim M, Grunert H, Kühne T, Zoubek A, Kevric M, Bürger H, Jürgens H, Mayer-Steinacker R, Gosheger G, Bielack SS. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42-50. (Pubitemid 43787907)
6. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89:884-93. (Pubitemid 47001642)
7. Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Viscomi C, Masciari S, Tassone P, Abbruzzese A, Venuta S. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother. 2005;54:1-10. (Pubitemid 40064480)
8. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427-36.
9. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020-34.
10. Lipton JH, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, Brummendorf T, Yoo K, Bergstrom B; Pegasys CML Study Group. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. 2007;48:497-505. (Pubitemid 46487756)
11. Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Leukemia. 2000;14:389-92. (Pubitemid 30142860)
12. Tsavaris N, Baxevanis C, Kosmidis P, Papamichael M. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. Cancer Immunol Immunother. 1996;43:94-102. (Pubitemid 26385226)
13. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-7.
14. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-80. (Pubitemid 32391207)
15. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27:2916-23.
16. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, Furuse K, Minamizaki T, Kawaguchi N, Yamawaki S. Multi-institutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009;14:397-404.
17. Kimura H, Tsuchiya H, Shirai T, Nishida H, Hayashi K, Takeuchi A, Ohnari I, Tomita K. Caffeine-potentiated chemotherapy for metastatic osteosarcoma. J Orthop Sci. 2009;14:556-65.
18. Kawaguchi N, Matumoto S, Manabe J. New method of evaluating the surgical margin and safety margin for musculoskeletal sarcoma, analysed on the basis of 457 surgical cases. J Cancer Res Clin Oncol. 1995;121:555-63.
19. Huvos AG. Bone tumors: diagnosis, treatment, and prognosis. 2nd ed. Philadelphia: WB Saunders; 1991. p 85-155.
20. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-28.
21. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
23. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC cancer staging manual. 6th ed. Chicago: The American Joint Committee on Cancer; 2002.
24. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology. 2009;77:400-10.
25. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28:3366-79.
26. Kondo M, Nagano H, Sakon M, Yamamoto H, Morimoto O, Arai I, Miyamoto A, Eguchi H, Dono K, Nakamori S, Umeshita K, Wakasa K, Ohmoto Y, Monden M. Expression of interferon alpha/beta receptor in human hepatocellular carcinoma. Int J Oncol. 2000;17:83-8.
27. Kamai T, Yanai Y, Arai K, Abe H, Yamanishi T, Kurimoto M, Yoshida K. Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis. BMC Cancer. 2007;7:159.
28. Saidi RF, Remine SG, Jacobs MJ. Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer. HPB (Oxford). 2007;9:289-94. (Pubitemid 47263965)
29. Rosolen A, Todesco A, Colamonici OR, Basso G, Frascella E. Expression of type I interferon receptor in solid tumors of childhood. Mod Pathol. 1997;10:55-61. (Pubitemid 27090775)
30. Navarro S, Colamonici OR, Llombart-Bosch A. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod Pathol. 1996;9:150-6. (Pubitemid 26090181)
31. Yuan XW, Zhu XF, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol Sin. 2007;28:1835-41. (Pubitemid 350029330)
32. Yuan XW, Zhu XF, Liang SG, Fan Q, Chen ZX, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway. Life Sci. 2008;82:393-401.
33. Strander H. Interferons and osteosarcoma. Cytokine Growth Factor Rev. 2007;18:373-80. (Pubitemid 47302835)
34. Todesco A, Carli M, Iacona I, Frascella E, Ninfo V, Rosolen A. All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. Cancer. 2000;89:2661-6.